{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:25:40Z","timestamp":1787757940241,"version":"build-2784847793"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"abstract":"\n Background:<\/jats:title>\n Bevacizumab a recombinant humanized monoclonal antibody was approved in 2004 by US FDA for metastatic colorectal cancer. It is reported to cause potentially serious toxicities including severe hypertension, proteinuria, and congestive heart failure.<\/jats:p>\n <\/jats:sec>\n \n Aim:<\/jats:title>\n To correlate adverse event tetany with the use of bevacizumab.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods :<\/jats:title>\n World Health Organization's Uppsala Monitoring Centre, Sweden, for reporting of adverse drug reactions from all over the world, identified 7 cases with tetany-related symptoms to bevacizumab from four different countries. These 7 patients reported to UMC database developed adverse events described as musculoskeletal stiffness (1), muscle spasm (1), muscle cramps (1), lock jaw or jaw stiffness (4), and hypertonia (1), with hypocalcaemia.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n After detailed study of the possible mechanism of actions of bevacizumab and factors causing tetany, it is proposed that there is a possibility of tetany by bevacizumab, which may occur by interfering with calcium metabolism. Resorption of bone through osteoclasts by affecting VEGF may interfere with calcium metabolism. Another possibility of tetany may be due to associated hypomagnesaemia, hypokalemia, or hyponatremia.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Tetany should be considered as a one of the signs. Patient on bevacizumab should carefully watch for tetany-related symptoms and calcium and magnesium levels for their safety.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/0019-509x.75819","type":"journal-article","created":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T08:30:29Z","timestamp":1295857829000},"page":"31-33","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Tetany: Possible adverse effect of bevacizumab"],"prefix":"10.4103","volume":"48","author":[{"given":"SR","family":"Anwikar","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Maharashtra University of Health Sciences, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MS","family":"Bandekar","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Maharashtra University of Health Sciences, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TK","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Govt. Medical College, Bhavnagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PB","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Govt. Medical College, Bhavnagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NA","family":"Kshirsagar","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Maharashtra University of Health Sciences, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2011,2,10]]},"reference":[{"key":"R3-20260604","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (avstin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"R5-20260604","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2003.11.015","article-title":"Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: A national cancer institute organ dysfunction working group study","volume":"21","author":"Takimoto","year":"2003","journal-title":"J Clin Oncol"},{"key":"R10-20260604","doi-asserted-by":"crossref","first-page":"48745","DOI":"10.1074\/jbc.M309193200","article-title":"RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1\/2-dependent mechanism","volume":"278","author":"Henriksen","year":"2003","journal-title":"J Biol Chem"},{"key":"R11-20260604","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.matbio.2008.06.005","article-title":"VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin","volume":"27","author":"Yang","year":"2008","journal-title":"Matrix Biol"},{"key":"R12-20260604","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1177\/00220345010800100401","article-title":"Effects of vascular endothelial growth factor on osteoclast induction during tooth movement in mice","volume":"80","author":"Kuku","year":"2001","journal-title":"J Dent Res"},{"key":"R13-20260604","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/9467","article-title":"VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation","volume":"5","author":"Gerber","year":"1999","journal-title":"Nat Med"},{"key":"R14-20260604","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1681\/ASN.V1161085","article-title":"Terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells","volume":"11","author":"Esbrit","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R15-20260604","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-5793(00)01520-9","article-title":"Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts","volume":"473","author":"Nakagawa","year":"2000","journal-title":"FEBS Lett"},{"key":"R16-20260604","doi-asserted-by":"crossref","first-page":"14016","DOI":"10.1073\/pnas.0503544102","article-title":"VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice","volume":"102","author":"Niida","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R17-20260604","doi-asserted-by":"crossref","first-page":"15532","DOI":"10.1200\/jco.2007.25.18_suppl.15532","article-title":"A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors","volume":"18","author":"Cooney","year":"2007","journal-title":"J Clin Oncol"},{"key":"R19-20260604","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1634\/theoncologist.12-6-713","article-title":"FDA drug approval summary: Bevacizumab (Avastin\u00ae) plus carboplatin and paclitaxel as first-line treatment of advanced metastatic recurrent nonsquamous non-small cell lung cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncologist"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02223310-201148010-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:00:00Z","timestamp":1787756400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02223310-201148010-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.4103\/0019-509x.75819","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}